Publication shows significant benefits of using intraoperative Glycosorb® treatment for blood group incompatible pediatric heart transplants

Great Ormond Street Hospital for Children (GOSH) in London, UK, has been using Glycosorb® ABO in conjunction with pediatric blood group incompatible heart transplants since 2015. GOSH has now in a retrospective study compared blood group incompatible transplants performed with Glycosorb® ABO and plasma exchange.

Data were collected for all blood group incompatible heart transplants performed between January 1, 2000, and June 1, 2020, a total of 37 transplants. Of these, plasma exchange (PE) was used for 27 transplants and 10 were performed with intraoperative Glycosorb® treatment.

For practical reasons, PE was usually carried out only in smaller children due to the large volumes of blood products required for such treatment. When a recipient is exposed to multiple, for the recipient foreign donor sources (of other tissue), the risk of transfusion related complications increases, as well as the risk of haemodynamic instability. Glycosorb® ABO was primarily introduced to address these problems.

The study shows, among other things, that the Glycosorb®-treated patients were significantly older and that the amount of blood products used during hospitalization was significantly lower compared to the PE patients. The average age of the 27 children in the PE group was 0.7 years and 4.1 years for the 10 children in the Glycosorb® group.

In the article[1], the authors conclude that the use of Glycosorb® ABO means that blood group incompatible heart transplants can be performed even in older and larger children, thereby providing an opportunity to increase the number of recipients. Another conclusion is the significantly reduced use of blood products when using Glycosorb® ABO compared to PE. Glycosorb® ABO was introduced at GOSH in 2015 and until now GOSH has published three articles on the subject.

"As one of the world’s largest clinics for pediatric heart transplants, we are very happy and proud that GOSH uses Glycosorb® ABO as standard treatment for blood group incompatible heart transplants. Treatment with Glycosorb® ABO means that more children are given the opportunity to undergo transplantation in a safer way. These are key factors for further expansion in this segment." says Pontus Nobréus, CEO of Glycorex Transplantation AB.

Every year, more than 8,000 heart transplants are performed globally, of which up to 700 are pediatric transplants. Heart transplants are currently performed routinely in many pediatric centers and over 100 centers worldwide are reported in the International Thoracic Transplant Registry.

"This publication demonstrates the clinical breadth of our technology in the transplantation area and the potential that exists for Glycosorb® ABO even outside the kidney area." concludes Pontus Nobréus.

[1] Richard Issitt, John Booth, Richard Crook, Alex Robertson, Victoria Molyneux, Rebecca Richardson, Nigel Cross, Michael Shaw, Victor Tsang, Vivek Muthurangu, Neil J Sebire, Michael Burch, Matthew Fenton

Intraoperative anti-A/B immunoadsorption is associated with significantly reduced blood product utilisation with similar outcomes in paediatric ABO-incompatible heart transplantation

The Journal of Heart and Lung Transplantation 2021, ISSN 1053-2498
https://doi.org/10.1016/j.healun.2021.05.010

Optimizing blood for life – solutions for improved quality of life and better health economy

Glycorex’s unique molecular level technology that specifically selects and removes antibodies in the blood has opened up ground-breaking treatments and solutions in healthcare. The company’s medical devices enable transplants across the blood groups saving lives and providing health economic benefits by increasing the number of transplants. The company’s technology to treat blood is applied in several health care settings and a new disruptive product has recently been launched with the potential to increase availability of blood plasma. Several new products for the treatment of autoimmune diseases are under development.

Glycorex Transplantation AB (publ) is listed on NGM Main Regulated Equity (Nordic Growth Market) and is traded under the symbol GTAB B.

Contact

Pontus Nobréus, CEO,
Glycorex Transplantation AB
+46 70 606 01 09
pontus.nobreus@glycorex.com

For more information:
glycorex.com